Different formulations of botulinum toxin type A have different migration characteristics: a double‐blind, randomized study
Authors:
- 31 January 2008
- journal article
- research article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 7 (1) , 50-54
Abstract
Summary: Objective Different formulations of botulinum toxin type A (BoNTA) are not identical and may behave differently in clinical practice. The reportedly lower incidence of adverse effects with one formulation (from Allergan, Ltd.) relative to another (from Ipsen, Ltd.) may be due to differences in the degree of migration of the neurotoxin–protein complex from its injection site. A double‐blind, randomized, within‐subject pilot study was performed to compare the migration characteristics of each formulation.Methods Twelve healthy volunteers were randomly assigned to receive three 0.1 mL intradermal injections in their forehead: 4 U BoNTA (Allergan) on one side, 12 U BoNTA (Ipsen) on the contralateral side, and saline in the center. At day 14, Minor's iodine starch test was performed, and the subjects walked around a hot room to induce sweating. The appearance of each forehead was documented using Canfield photography and the area of each anhidrotic halo calculated using software.Results Overall, the area of anhidrosis was significantly larger with BoNTA (Ipsen) than BoNTA (Allergan) – mean ± SD of 2.7 ± 0.78 cm2 vs. 1.8 ± 0.65 cm2 (P = 0.005) – with the area of anhidrosis being greater with BoNTA (Ipsen) than BoNTA (Allergan) in 11 of the 12 subjects. Across all subjects, the area of anhidrosis was greater with BoNTA (Ipsen) than BoNTA (Allergan) by a mean of 77%.Conclusions BoNTA (Ipsen) migrates more than BoNTA (Allergan) under the conditions described. The lower potential of BoNTA (Allergan) to migrate promotes more precise localization of clinical effects, thereby helping to optimize the risk/benefit ratio.Keywords
This publication has 15 references indexed in Scilit:
- A Double‐Blind, Randomized, Comparative Study of Two Type A Botulinum Toxins in the Treatment of Primary Axillary HyperhidrosisDermatologic Surgery, 2007
- Pilot Study Comparing the Diffusion of Two Formulations of Botulinum Toxin Type A in Patients with Forehead HyperhidrosisDermatologic Surgery, 2007
- Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized studyJournal of the American Academy of Dermatology, 2006
- Botulinum neurotoxin — from laboratory to bedsideNeurotoxicity Research, 2006
- A double-blind, randomized, comparative study of DysportR vs. BotoxR in primary palmar hyperhidrosisBritish Journal of Dermatology, 2003
- Effect of Botulinum Toxin A on Facial Wrinkle Lines in KoreansOphthalmologica, 2002
- Costs of Treating Dystonias and Hemifacial Spasm with Botulinum Toxin APharmacoEconomics, 1997
- The therapeutic use of botulinum toxinExpert Opinion on Investigational Drugs, 1997
- Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasmGraefe's Archive for Clinical and Experimental Ophthalmology, 1997
- Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injectionsMovement Disorders, 1994